ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ZLDPF Zealand Pharma AS (PK)

125.20
0.70 (0.56%)
Last Updated: 15:41:42
Delayed by 15 minutes
Share Name Share Symbol Market Type
Zealand Pharma AS (PK) USOTC:ZLDPF OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.70 0.56% 125.20 124.00 125.85 125.20 125.20 125.20 1,397 15:41:42

Report of Foreign Issuer (6-k)

16/05/2018 5:06pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 6-K

 


 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May 16, 2018

 


 

Commission File Number: 001 - 38178

 


 

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 


 

Smedeland 36
2600 Glostrup (Copenhagen)
Denmark

(Address of principal executive offices)

 


 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x            Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Zealand Pharma A/S or the Company, dated May 16, 2018, announcing the company’s interim report for the first three months of 2018.

 

Furnished as Exhibit 99.2 to this Report on Form 6-K is the Company’s slide presentation on the financial results of the Company for the first three months of 2017, referenced in the press release.

 

Exhibits 99.1 and 99.2 to this report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, or the Securities Act, or the Exchange Act.

 

 

 



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Zealand Pharma A/S

 

 

 

 

 

By:

/s/ Mats Blom

 

 

 

 

 

 

Name:

Mats Blom

 

 

Title:

Chief Financial Officer

 

Date: May 16, 2018

 

2



 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press release dated May 16, 2018

 

 

 

99.2

 

Slide Presentation on the Company’s Financial Results for the First Three Months of Fiscal Year 2018

 

3


1 Year Zealand Pharma AS (PK) Chart

1 Year Zealand Pharma AS (PK) Chart

1 Month Zealand Pharma AS (PK) Chart

1 Month Zealand Pharma AS (PK) Chart